News
From innovation in manufacturing to more-flexible regulation and better communication with payers, much needs to happen to ...
SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.
11h
GlobalData on MSNHansa’s Idefirix shows potential as pre-treatment to ElevidysHansa Biosciences’ Idefirix (imlifidase) has reduced patients’ antibodies to a level that allows dosing in patients with Duchenne muscular dystrophy (DMD) with Sarepta and Roche’s Elevidys ...
US Food and Drug Administration Commissioner Marty Makary said he’s trying to persuade Vinay Prasad, the agency’s former head of gene therapy and vaccines, to return to the FDA after his abrupt ...
Swedish biotech Hansa Biopharma on Friday released encouraging top-line results from three patients with Duchenne muscular ...
2h
Stockhead on MSNHealth Check: Audeara strives to be ‘the next Cochlear’ in affordable hearing collabCochlear’s Baha devices – as in bone-anchored hearing aid – cost around $10,000 locally. Strictly speaking, the $4 million ...
Investing.com -- US Food and Drug Administration Commissioner Marty Makary is attempting to convince Vinay Prasad, who recently left his position as head of gene therapy and vaccines, to return to the ...
Through our Venable FDA Pulse series, we report on critical developments within the Food and Drug Administration (FDA or Agency) that may affect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results